Nabumetone

Nabumetone

SCHEMBL3853067

COc1ccc2cc(CCC(C)=O)ccc2c1.COc1ccc2cc(CCC(C)=O)ccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGS2

The experimentally established mechanism targets of Nabumetone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 known ✓ P35354 1/20 0.58
CYP1A2 P05177 2/20 1.00
KDM4E B2RXH2 2/20 1.00
LMNA P02545 2/20 1.00
MAPT P10636 2/20 1.00
NPC1 O15118 1/20 1.00
TP53 P04637 1/20 1.00
CYP3A4 P08684 1/20 1.00
MAOA P21397 1/20 1.00
SLC6A2 P23975 1/20 1.00
RAB9A P51151 1/20 1.00
SLC6A3 Q01959 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
PTGS1 P23219 1/20 0.61
AKR1C3 P42330 1/20 0.61
AKR1C2 P52895 1/20 0.61
HCAR2 Q8TDS4 1/20 0.55
F2RL1 P55085 1/20 0.51
HSD17B1 P14061 1/20 0.50
HSD17B2 P37059 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nabumetone SCHEMBL29373228 1.00 CYP1A2 (1.00) CYP1A2KDM4ELMNAMAPTNPC1
Nabumetone SCHEMBL29570823 1.00 CYP1A2 (1.00) CYP1A2KDM4ELMNAMAPTNPC1
Nabumetone SCHEMBL2256 1.00 CYP1A2 (1.00) CYP1A2KDM4ELMNAMAPTNPC1
Nabumetone SCHEMBL28775077 0.98 CYP1A2 (0.97) CYP1A2KDM4ELMNAMAPTNPC1
Nabumetone SCHEMBL104942 0.98 CYP1A2 (0.97) CYP1A2KDM4ELMNAMAPTNPC1
Nabumetone SCHEMBL23064140 0.97 CYP1A2 (0.94) CYP1A2KDM4ELMNAMAPTNPC1
Nabumetone SCHEMBL7554060 0.95 CYP1A2 (0.91) CYP1A2KDM4ELMNAMAPTNPC1
Nabumetone SCHEMBL3362072 0.93 RAB9A (0.86) CYP1A2KDM4ELMNAMAPTNPC1
Nabumetone SCHEMBL2325715 0.91 CYP1A2 (0.83) CYP1A2KDM4ELMNAMAPTNPC1
SCHEMBL17288829 0.90 CYP1A2 (0.82) CYP1A2KDM4ELMNAMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012166973-A1 METHODS FOR PROMOTING CELL REPROGRAMMING SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2012-12-06 WO disclosed
WO-2012151309-A1 METHODS FOR REGULATING INDUCED PLURIPOTENT STEM CELL GENERATION AND COMPOSITIONS THEREOF SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2012-11-08 WO disclosed
EP-2054052-A1 DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM Vicus Therapeutics SPE 1, LLC (US) 2009-05-06 EP disclosed
WO-2008014471-A1 DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM VICUS THERAPEUTICS SPE 1, LLC (US) 2008-01-31 WO disclosed
WO-2006083508-A2 COMBINATIONS OF SUPEROXIDE DISMUTASE MIMETICS AND NONSTEROIDAL ANALGESIC/ANTI-INFLAMMATORY DRUGS METAPHORE PHARMACEUTICALS INC. (US) 2006-08-10 WO disclosed
EP-1551370-A1 AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN IDEA AG (DE) 2005-07-13 EP disclosed
EP-1549742-A1 METHOD FOR SELECTION OF COMPOUNDS WHICH INHIBIT CLONAL CELL GROWTH AND USE THEREOF Tjötta, Enok (NO) 2005-07-06 EP disclosed
WO-2004055175-A1 METHOD FOR SELECTION OF COMPOUNDS WHICH INHIBIT CLONAL CELL GROWTH AND USE THEREOF TJOETTA ENOK (NO) 2004-07-01 WO disclosed
WO-2004032900-A1 AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN IDEA AG (DE) 2004-04-22 WO disclosed
US-20040028582-A1 Crystallization process for producing fine crystal products SMITHKLINE BEECHAM CORPORATION 2004-02-12 US disclosed